Life Sciences & Biotechnology

Title :

Area of research :

Focus area :

Principal Investigator :

Timeline Start Year :

Timeline End Year :

Contact info :

Executive Summary :

Objective: The overall aim of the mission project is to develop innovative and novel processes for repurposing drugs of COVID-19 towards affordable health care. The objectives of the mission project are: To develop the complete process know-how of 23 APIs; To develop the analytical method for the key starting materials of the proposed APIs; To develop a cost-effective, indigenous process for all intermediates and API’s; To demonstrate the know-how process for each API on a minimum 25 g scale; To demonstrate the know-how process for intermediates on 500g scale; To study the polymorphism, wherever possible; To identify the combination of drugs towards COVID19 through molecular modelling study; To generate the clinical data for combination of drugs towards COVID-19.

Summary: CSIR has taken up a mission mode project with the aim of development of cost effective and complete process know-how for 23 selected API molecules to treat COVID 19. The APIs being developed are: Centhaquin, Umifenovir, Tilorone, Baloxavir, Saquinavir, Remdesivir, Dalargin, KSMs-Hydroxychloroquine, Ribavirin, EIDD-1931, Phosphonate Fragment of Remdesivir, Barcitinib, Ruxolitinib, Lopinavir-KSM, Ritonavir -KSM, EIDD 2801, and Galidesvir. The project is currently in implementation at CSIR-IICT, Hyderabad along with 8 other constituent laboratories of CSIR for a short duration of nine months. These processes shall be licensed / transferred to pharmaceutical industries to ensure access to these pharmaceuticals at affordable prices. The successful completion of the project will ensure the availability of these drugs at affordable price for the Indian population. This will also reduce the burden of import of anti COVID-19 drugs. Thus, the project proposes to contribute to GoIProgrammes to ensure better health for all through innovation in the area of pharmaceuticals.

Implementing Agency :

Funding Agency :

Source (more info) :